pharma · Hemophilia A With Inhibitor · Hemophilia A · CPRX
CATALYST PHARMACEUTICALS
CATALYST PHARMACEUTICALS, INC.
CATALYST PHARMACEUTICALS clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, US
- Founded
- 2002
- Employees
- 179
- Programs
- 23
- Drugs
- 20
- Patents
- 61
CATALYST PHARMACEUTICALS projects
6 ClinicalTrials.gov programs sponsored by CATALYST PHARMACEUTICALS.
CATALYST PHARMACEUTICALS has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Lambert Eaton Myasthenic Syndrome
2 trials -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, Generalized
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, MuSK
1 trial -
BT-001
CATALYST PHARMACEUTICALS, INC.
Type2 Diabetes
1 trial -
MarzAA
CATALYST PHARMACEUTICALS, INC.
Hemophilia A With Inhibitor
1 trial -
amifampridine phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenic Syndromes, Congenital
1 trial
Frequently asked questions
How many clinical projects does CATALYST PHARMACEUTICALS have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.